An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor EL).

Trial Profile

An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor EL).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Oasmia Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2016 According to an Oasmia Pharmaceuticals media release, results from this trial will form the basis of the marketing application to the US FDA anticipated to be submitted in the end of 2016/2017.
    • 27 Apr 2016 Results of overall survival published in an Oasmia Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top